# Post-Experiment Governance Review - EXP-013

**Experiment:** EXP-013 - Incremental Substrate Validation
**Stage:** 8 (post-experiment)
**Date:** 2026-06-04
**Artifacts reviewed:** `audit.md`, `results.md`, `report.md`, `results/`, `python/experiments/INDEX.md`, `docs/experiments-docs/INDEX.md`

## Verdict

```text
VERDICT: APPROVE
```

## Review

| Check | Finding | Status |
|---|---|---|
| Audit completeness | Audit verifies predeclaration token, EXP-001 dependency, real-price marginal estimator, recovery, redundancy null, and denominator accounting. | PASS |
| Results interpretation | `results.md` correctly treats recovery PASS and absence of phantom positive edge as substrate support. | PASS |
| Report accuracy | `report.md` reports 108/108 positive recovery PASS and 0 phantom-edge redundancy cells. | PASS |
| Index updates | Both indexes include EXP-013 with Track B P0 substrate PASS. | PASS |
| Governance constraints | First-70-percent analysis slice only; no chart-type or real-candidate scope creep; cost-dominated nulls are described honestly. | PASS |

## Notes

The cost-dominated null cells are negative cost-drag outcomes from the pre-execution-confirmed cost model and do not undermine the binding no-phantom-positive control.
